Sustained Full Monotherapy Crenolanib Dosing Was Tolerable in Older Patients

Crenolanib was administered starting on day 9 of the chemotherapy cycle and continuing until 72 hours before the next chemotherapy cycle, allowing for sustained FLT3 inhibition, unlike other TKIs

Induction Regimen

Crenolanib: 100 mg/m2/Day
Day 9 – 9 continuousy until 72 hrs prior to next chemotherpy

Sustained Full Monotherapy Crenolanib Dosing Was Tolerable in Older Patients

Crenolanib + Daunorubicin

10/14 Evaluable Patients Achieved Remission with Count Recovery After 1 Cycle of Induction

71% of evaluable patients achieved a CR/CRi after one cycle of induction chemotherapy The overall response rate to crenolanib combination therapy was 86% for evaluable patients

Induction Chemotherapy Regimen

Cytarabine + Daunorubicin (n=12)

8/12 (67%)

Cytarabine + Idarubicin (n=5)

2/2 (100%)

Total Evaluable (n=14)

10/14 (71%)

Conclusions

- These results suggest that crenolanib is safe and tolerable given sequentially with standard induction chemotherapy in older patients aged 61-75 years.
- Crenolanib combination therapy provided promising overall survival rates, with low rates of early mortality.

Background

Older AML patients often present with comorbidities and may have a compromised ability to tolerate intensive chemotherapy. These patients are more likely to have AML secondary to MOS/MPN and are considered to have a biologically distinct disease compared to their younger counterparts, with more frequent occurrences of adverse-risk cytogenetic abnormalities and mutations in genes regulating epigenetic modifications. In addition, the heterogeneity of driver mutations within a single patient contributes to limited responses to standard induction chemotherapy. While FLT3 mutations occur in this population, they are often subclonal, adding to the challenge of eradicating AML in older adult patients. Studies combining sorafenib or midostaurin with standard induction chemotherapy have shown reduced rates of major improvements in response rates and survival, and relapse, both early and late, remain a major concern.

There is a major unmet need for optimizing chemotherapy and TKI treatment in this medically fragile population. We here report the safety and efficacy results in newly diagnosed older patients with FLT3 mutant AML treated with crenolanib, a Type II FLT3 inhibitor, in combination with intensive induction and consolidation chemotherapy (NC10283177).

Methods: Fifteen consecutively treated patients, aged 61-75 (median age: 68), at four academic cancer centers were included in this analysis. Patients received 7+3 induction with cytarabine 100 mg/m2 for 7 days and either daunorubicin 60 mg/m2 or idarubicin 12 mg/m2 for 3 m. Crenolanib 100 mg/m2 was administered continuously starting 24 hours after chemotherapy until 72 hours prior to the next induction chemotherapy cycle. Consolidation consisted of up to 4 cycles of high-dose cytarabine (HDAC: 1 g/m2) on days 1, 3, and 5 with crenolanib starting 24 hours after the final HDAC dose. Eligible patients provided to allelic hematopoietic stem cell transplant (HSCT). Maintenance with crenolanib at 100 mg TID was started after HDAC or 30-90 days after HCT for up to 12 cycles.

Results: Fourteen patients completed induction chemotherapy (one patient withdrew consent at day 19). Crenolanib could be safely combined with either daunorubicin or idarubicin based induction chemotherapy. The most common adverse events (grade 3) were diarrhea, nausea, and febrile neutropenia. Ten of 14 patients were able to receive full doses of crenolanib during induction. The major reason for dose reduction was edema in 3 patients and GI bleeding in 1 patient. There was one treatment-related death, with 93% survival at 30 and 60 days and 87% survival at 100 days.

Complete remissions with full count recovery (CR) were achieved in 10 of 14 evaluable patients after just one cycle of induction chemotherapy. Two patients achieved a complete remission after induction for an overall CR rate of 86%. Of the 12 patients who achieved CR, 10 patients received HSAC consolidation, with two patients unable to receive consolidation therapy on study. Three patients received crenolanib maintenance after multiple cycles of HDAC consolidation. Six patients underwent HSCT and 3 received crenolanib maintenance.

As of July 2019, median OS for the intent to treat population is 20.2 months. One-year survival was 67% and 5 patients remain alive and in remission. All 10 long-term survivors were ≥70 years old. All surviving patients received either multiple cycles of HDAC or HDAC plus transplant, and 4/5 underwent crenolanib maintenance. The patient who did not receive transplant completed 3 cycles of HDAC consolidation and a full year of crenolanib maintenance.

Summary/Conclusion: This safety study shows that crenolanib can be combined at full doses (100 mg TID) for the duration of 7+3 induction, consolidation, and maintenance in older patients with FLT3. Therapy was relatively well tolerated, with less than one third of patients requiring dose reductions. Long-term survival rates are encouraging in this high-risk population, but additional studies are needed to confirm the efficacy of this combination in older adults.

Overall Survival Patients Aged 61-70

Median OS for patients aged 61-70 (n=12) was 26.8 months.

References:


Crenolanib was Well Tolerated Following High dose Cytarabine Consolidation in Older Patients

- 10/12 patients who achieved CR received consolidation
- No patients required dose reductions during consolidation

Crenolanib + Daunorubicin (n=11)

8/11 (73%)

Crenolanib + Idarubicin (n=5)

2/5 (40%)

Patients Withdrawed Crenolanib

Background

AML5G16-10 study of midostaurin given in combination with chemotherapy
- 78% of patients aged 60-71 years achieved a CR/CRI (n=86) + 48% of patients aged 60-71 achieved a CR with full count recovery
- For patients aged 60-71, the 2-year OS was 45.6%

There remains an unmet need for therapy options in this older patient population.